GT Biopharma Management
Management criteria checks 3/4
GT Biopharma's CEO is Michael Breen, appointed in Mar 2022, has a tenure of 2.17 years. total yearly compensation is $1.89M, comprised of 26% salary and 74% bonuses, including company stock and options. directly owns 2.07% of the company’s shares, worth €80.35K. The average tenure of the management team and the board of directors is 2.3 years and 3.4 years respectively.
Key information
Michael Breen
Chief executive officer
US$1.9m
Total compensation
| CEO salary percentage | 26.0% |
| CEO tenure | 2.2yrs |
| CEO ownership | 2.1% |
| Management average tenure | 2.3yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$15m |
| Mar 31 2023 | n/a | n/a | -US$16m |
| Dec 31 2022 | US$2m | US$493k | -US$21m |
| Sep 30 2022 | n/a | n/a | -US$33m |
| Jun 30 2022 | n/a | n/a | -US$32m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$3m | US$63k | -US$58m |
Compensation vs Market: Michael's total compensation ($USD1.89M) is above average for companies of similar size in the German market ($USD400.67K).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
CEO
Michael Breen (60 yo)
2.2yrs
Tenure
US$1,892,293
Compensation
Mr. Michael Martin Breen serves as Interim Chief Executive Officer at GT Biopharma, Inc. since March 02, 2022. Mr. Breen serves as an Executive Chairman at GT Biopharma, Inc. since November 08, 2021 and se...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Executive Chairman | 2.2yrs | US$1.89m | 2.07% € 80.3k | |
| CFO & Secretary | 2.3yrs | US$993.38k | 0.85% € 32.8k | |
| Consulting Chief Scientific Officer | 4.8yrs | no data | no data |
2.3yrs
Average Tenure
Experienced Management: OXIA's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Executive Chairman | 3.3yrs | US$1.89m | 2.07% € 80.3k | |
| Consulting Chief Scientific Officer | 6.7yrs | no data | no data | |
| Independent Director | less than a year | no data | 0% € 0 | |
| Independent Director | 3.3yrs | US$1.35m | 0% € 0 | |
| Independent Vice Chairman | 3.5yrs | US$548.71k | 0.85% € 33.1k | |
| Scientific Advisor | no data | no data | no data | |
| Chairman of Science Advisory Board | 3.6yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | 3.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.8yrs | no data | no data |
3.4yrs
Average Tenure
73.5yo
Average Age
Experienced Board: OXIA's board of directors are considered experienced (3.4 years average tenure).